Search Results for: mesoblast

Mesoblast (MSB) buys Osiris (OSIR) stem cell unit

The Australian stem cell biotech Mesoblast (MSB) has reportedly reached a deal with the American stem cell biotech Osiris (OSIR) to buy Osiris’ mesenchymal stem cell (MSC) unit. This is a big development in the MSC field. Osiris and Mesoblast are two major players in this particular subfield of the stem cell world so this deal, …

Mesoblast (MSB) buys Osiris (OSIR) stem cell unit Read More »

Viacyte & Mesoblast present at CIRM Meeting

Allan Robins of Viacyte (pictured at left–sorry for the fuzzy image) and Paul Simmons of Mesoblast presented this morning at the CIRM Grantee Meeting. Both talks were outstanding. Robins went first. He started by saying how Viacyte had a productive pre-IND meeting with the FDA last year. I believe a target for them is to …

Viacyte & Mesoblast present at CIRM Meeting Read More »

Stem cell therapy for heart disease: what you need to know

stem cell therapy for hearts

How much promise is there today for stem cell therapy for heart disease? Where do things stand with the clinical research? Patients regularly ask me these kinds of questions. The goal of today’s post is to update you on where things stand. What’s in this post Stem Cell Therapy | Clinical Trials | Delivery of …

Stem cell therapy for heart disease: what you need to know Read More »

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best

Mesoblast stock

A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going …

2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell therapy arena. Today …

24 cell therapy & stem cell stocks I’m following Read More »

Fact-check: F grade for irresponsible stem cell COVID-19 cure piece

vitro biopharma stem cells covid 19

At times there’s been seriously bad journalism covering COVID-19 itself including implications of various things being a COVID cure. Of course, media coverage of stem cell research itself sometimes ends up being a train-wreck of hype too. More recently we’ve seen irresponsible journalism also around the specific idea of stem cells for COVID-19, but sometimes …

Fact-check: F grade for irresponsible stem cell COVID-19 cure piece Read More »

Small umbilical cord stem cell COVID-19 trial: sign of efficacy?

Cord-blood-autism

A new paper today in Stem Cells Translational Medicine on a small COVID-19 Phase 1/2a trial using an umbilical cord stem cell product reports a surprising degree of possible efficacy. What’s the scoop here and could there be some hype in the media about this new study such as one of the authors describing the …

Small umbilical cord stem cell COVID-19 trial: sign of efficacy? Read More »

Recommended reads: MSCs, vision, endothelial cells, more

wang et al 2020 science advances

What a year 2020 was, but there was still plenty of great science, which continues now in 2021 including published research like today’s recommended pieces and there’s one thread on MSCs today. The Niche new look, more features, and a Medical Advisory Board for 2021 Before we get to the recommended reads, note that 2021 …

Recommended reads: MSCs, vision, endothelial cells, more Read More »